Tango Therapeutics, Inc. (TNGX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q2 '21: 22.4M Q3 '21: 40.5M Q4 '21: 37M Q1 '22: 36.4M Q2 '22: 24M Q3 '22: 24.2M Q4 '22: 24.9M Q1 '23: 24.9M Q2 '23: 33.7M Q3 '23: 37.5M Q4 '23: 36.5M Q1 '24: 37.2M Q2 '24: 42.5M Q3 '24: 43.4M Q4 '24: 42.1M Q1 '25: 41M Q2 '25: 24.3M Q3 '25: 66.5M Q4 '25: 62.4M Q1 '26: 57M Q2 '26: 53.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-180M -120M -60M 0 60M 120M 180M Q2 '21: -52.3M Q3 '21: -45.1M Q4 '21: -58.2M Q1 '22: -71.5M Q2 '22: -92.1M Q3 '22: -102.5M Q4 '22: -111.1M Q1 '23: -116M Q2 '23: -114M Q3 '23: -109.7M Q4 '23: -114.2M Q1 '24: -126.1M Q2 '24: -132.4M Q3 '24: -139.7M Q4 '24: -145.6M Q1 '25: -145.9M Q2 '25: -157.3M Q3 '25: -110.3M Q4 '25: -111.3M Q1 '26: -117.5M Q2 '26: -136.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q4 '20: -43.2M Q1 '21: -47.4M Q2 '21: -43.5M Q3 '21: -36.3M Q4 '21: -58.2M Q1 '22: -71.3M Q2 '22: -91.7M Q3 '22: -101.2M Q4 '22: -108.2M Q1 '23: -111M Q2 '23: -106.8M Q3 '23: -100M Q4 '23: -101.7M Q1 '24: -111.7M Q2 '24: -116.5M Q3 '24: -123.4M Q4 '24: -130.3M Q1 '25: -132.3M Q2 '25: -145.6M Q3 '25: -100.5M Q4 '25: -101.6M Q1 '26: -107.2M Q2 '26: -123.7M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q2 '21: -21.5M Q3 '21: -42.9M Q4 '21: -59.5M Q1 '22: -75.6M Q2 '22: -99.6M Q3 '22: -97.7M Q4 '22: -109.1M Q1 '23: -114.3M Q2 '23: -107.3M Q3 '23: -118.8M Q4 '23: -118M Q1 '24: -120.9M Q2 '24: -120.1M Q3 '24: -122.3M Q4 '24: -131.5M Q1 '25: -135.3M Q2 '25: -148.3M Q3 '25: -145.8M Q4 '25: -138.9M Q1 '26: -141.5M Q2 '26: -143.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q3 '21: -44.5M Q4 '21: -61.4M Q1 '22: -78.8M Q2 '22: -104.4M Q3 '22: -105.1M Q4 '22: -116.8M Q1 '23: -121.1M Q2 '23: -112.9M Q3 '23: -121.1M Q4 '23: -119.5M Q1 '24: -122M Q2 '24: -120.8M Q3 '24: -123.2M Q4 '24: -132.3M Q1 '25: -136M Q2 '25: -149.2M Q3 '25: -146.8M Q4 '25: -139.9M Q1 '26: -142.5M Q2 '26: -144.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 60M 120M 180M Q2 '21: 48.5M Q3 '21: 70.2M Q1 '22: 87.7M Q2 '22: 87.8M Q3 '22: 87.9M Q1 '23: 88.2M Q2 '23: 88.4M Q3 '23: 97M Q1 '24: 108.2M Q2 '24: 108.3M Q3 '24: 108.5M Q1 '25: 110.3M Q2 '25: 110.5M Q3 '25: 117.8M Q1 '26: 143.6M Q2 '26: 149.9M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q2 '21: -1.14 Q3 '21: -0.66 Q4 '21: -0.92 Q1 '22: -0.92 Q2 '22: -1.11 Q3 '22: -1.16 Q4 '22: -1.23 Q1 '23: -1.26 Q2 '23: -1.21 Q3 '23: -1.11 Q4 '23: -1.08 Q1 '24: -1.11 Q2 '24: -1.12 Q3 '24: -1.16 Q4 '24: -1.20 Q1 '25: -1.21 Q2 '25: -1.32 Q3 '25: -0.92 Q4 '25: -0.88 Q1 '26: -0.84 Q2 '26: -0.86 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.